TY - JOUR
T1 - Hemostatic molecular markers in nephrotic syndrome
AU - Chen, Tsai‐Yun ‐Y
AU - Huang, Chieng‐Chung ‐C
AU - Tsao, Chao‐Jung ‐J
PY - 1993/12
Y1 - 1993/12
N2 - Quantitative changes of hemostatic molecular markers were studied in patients with nephrotic syndrome. The plasma levels of fibrinopeptide A (FPA), thrombin‐antithrombin III complex (TAT), products of thrombin activation, and fragment F1 + 2 (F1 + 2), a product of prothrombin activation, were measured by enzyme immunoassay in 21 patients with nephrotic syndrome and in 16 normal controls. The mean value of FPA was 17.5 ± 7.5 ng/ml (mean ± SD) in nephrotic patients and 4.5 ± 0.3 ng/ml in normal controls (P < 0.02); F1 + 2 concentration was 1.4 ± 0.3 ng/ml in nephrotic patients and 0.5 ± 0.1 ng/ml in normal controls (P < 0.001); TAT level was 1.0 ± 0.3 μg/l in nephrotic patients and 0.2 ± 0.1 μg/l in normal controls (P < 0.05). These data indicated intravascular hemostasis activation. Based on these results, we propose that low antithrombin III level in nephrotic patients may be due to both urinary loss and intravascular consumption. © 1993 Wiley‐Liss, Inc.
AB - Quantitative changes of hemostatic molecular markers were studied in patients with nephrotic syndrome. The plasma levels of fibrinopeptide A (FPA), thrombin‐antithrombin III complex (TAT), products of thrombin activation, and fragment F1 + 2 (F1 + 2), a product of prothrombin activation, were measured by enzyme immunoassay in 21 patients with nephrotic syndrome and in 16 normal controls. The mean value of FPA was 17.5 ± 7.5 ng/ml (mean ± SD) in nephrotic patients and 4.5 ± 0.3 ng/ml in normal controls (P < 0.02); F1 + 2 concentration was 1.4 ± 0.3 ng/ml in nephrotic patients and 0.5 ± 0.1 ng/ml in normal controls (P < 0.001); TAT level was 1.0 ± 0.3 μg/l in nephrotic patients and 0.2 ± 0.1 μg/l in normal controls (P < 0.05). These data indicated intravascular hemostasis activation. Based on these results, we propose that low antithrombin III level in nephrotic patients may be due to both urinary loss and intravascular consumption. © 1993 Wiley‐Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0027374633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027374633&partnerID=8YFLogxK
U2 - 10.1002/ajh.2830440411
DO - 10.1002/ajh.2830440411
M3 - Article
C2 - 8238000
AN - SCOPUS:0027374633
SN - 0361-8609
VL - 44
SP - 276
EP - 279
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 4
ER -